At a glance
ClinicalIndex Comparison Record- ✓Untreated stage 1 primary hypertension with systolic BP 140-159 mmHg and diastolic BP 90-99 mmHg
- ✕Cardiopulmonary disease by history or physical examination
- ✕Serum creatinine ≥1.5 mg/dL
- ✕Diabetes mellitus or other systemic illness
- ✕Left ventricular hypertrophy by echocardiography or ECG
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neural Mechanisms of Thiazide-induced Insulin Resistance
In Brief
A Phase 4 clinical trial evaluating Study#1: chlorthalidone (CTD), titrated dose, Study #1: spironolactone (SP), titrated dose, and 3 other interventions for Hypertension. Completed, enrolled 166 participants across 2 sites.
Detailed Summary
Thiazide medications are often prescribed for individuals with high blood pressure, but research has shown that they may increase an individual's risk of developing diabetes. While it is unknown exactly how thiazide causes this response, it is likely that the nervous system is somehow involved. This study will evaluate the role of the nervous system in sugar metabolism, as well as determine the effect of thiazide and other medications on individuals with high blood pressure.
Study Details
Timeline
Interventions
Participants in study #1 will receive 3 months of chlorthalidone (12.5-25 mg/d) at the dose titrated to achieve 24-h ambulatory BP \< 130/80 mmHg
Participants in study #1 will receive 3 months spironolactone (25-75 mg/d), at the dose titrated to achieve 24-h ambulatory BP \< 130/80 mmHg.
Participants in study #2 will receive 3 months of fixed-dose of CTD, at 25 mg/d.
Participants in study #2 will receive 3 months of fixed-dose SP at 25 mg daily.
Participants in study #2 will receive 3 months of fixed-dose IR at150 mg daily.